Moneyta · stock research · no sign-up needed
ANGO
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (Q1 FY2027)
$81M
+0.9% y/y
Net income (Q1 FY2027)
-$7M
as filed with the SEC
Institutions holding
161
+14 last quarter
Overview · ANGIODYNAMICS INC
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ab…
Management team
- Mr. Scott Centea · Senior VP & GM of Endovascular TherapiesFind on LinkedIn
- Ms. Kim L. Seabury · Senior Vice President of Information TechnologyFind on LinkedIn
- Mr. Warren G. Nighan · Senior Vice President of Quality & Regulatory AffairsFind on LinkedIn
- Ms. Marna I. Bronfen-Moore · Senior Vice President of Human ResourcesFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
members see every cardRead the full desk report on ANGO
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.